Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.

Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay. Cardiovasc Drugs Ther. 2020 08; 34(4):443-461.

View in: PubMed

subject areas

AMP-Activated Protein Kinases
Animals
Benzhydryl Compounds
Diabetes Mellitus, Type 2
Diabetic Cardiomyopathies
Disease Models, Animal
Disease Progression
Enzyme Activation
Fibrosis
Glucosides
Inflammasomes
Male
Mechanistic Target of Rapamycin Complex 2
Mice, Inbred C57BL
Myocytes, Cardiac
NLR Family, Pyrin Domain-Containing 3 Protein
Purinergic P2Y Receptor Antagonists
Signal Transduction
Stroke Volume
TOR Serine-Threonine Kinases
Ventricular Function, Left
Ventricular Remodeling

authors with profiles

YOCHAI BIRNBAUM